Profil bibliographique

Gerhard Siemeister

Informations fournies par OpenAlex. Research Africa ne déduit ni nationalité, ni poste, ni coordonnées personnelles.

240Publications signalées

5976Citations signalées

1Affiliations récentes

Les institutions déclarées

Nuvisan (Germany)

Les domaines associés

Cancer-related Molecular PathwaysCancer Treatment and PharmacologyMicrotubule and mitosis dynamicsAdvanced Breast Cancer TherapiesCancer Mechanisms and Therapy

Les publications récentes

Accès ouvert 2025 article OpenAlex

Polo-like kinase 1–inhibitor co-complex structures via the surface-entropy reduction approach and a DARPin-assisted approach

Uwe Eberspaecher, Arndt A. Schmitz, Gerhard Siemeister, Ulf Bömer et autres

de, pt (code pays fourni par la source)

1 citation Acta Crystallographica Section D Structural Biology

2025 dataset OpenAlex

CRYSTAL STRUCTURE OF WILD-TYPE PLK1 KINASE DOMAIN IN COMPLEX WITH THIAZOLIDINONE INHIBITOR COMPOUND 1 AND A SELECTIVE DARPIN

R.C. Hillig, Pedro M. Matias, Tiago M. Bandeiras, Volker Schulze et autres

0 citations Worldwide Protein Data Bank

2023 conference-abstract OpenAlex

Abstract 311: Optimization of treatment schedule for the combination therapy of ATR inhibitor elimusertib and PARP inhibitor niraparib in preclinical tumor models

Antje M. Wengner, Gerhard Siemeister, Bart A. Ploeger, Lisa Ehresmann et autres

de (code pays fourni par la source)

1 citation Cancer Research

Accès ouvert 2023 other OpenAlex

Data from BAY 1000394, a Novel Cyclin-Dependent Kinase Inhibitor, with Potent Antitumor Activity in Mono- and in Combination Treatment upon Oral Application

Gerhard Siemeister, Ulrich Lücking, Antje M. Wengner, Philip Lienau et autres

0 citations

Accès ouvert 2023 supplementary-materials OpenAlex

Supplementary Figure 3 from BAY 1000394, a Novel Cyclin-Dependent Kinase Inhibitor, with Potent Antitumor Activity in Mono- and in Combination Treatment upon Oral Application

Gerhard Siemeister, Ulrich Lücking, Antje M. Wengner, Philip Lienau et autres

0 citations

Accès ouvert 2023 supplementary-materials OpenAlex

Supplementary Figure 2 from BAY 1000394, a Novel Cyclin-Dependent Kinase Inhibitor, with Potent Antitumor Activity in Mono- and in Combination Treatment upon Oral Application

Gerhard Siemeister, Ulrich Lücking, Antje M. Wengner, Philip Lienau et autres

0 citations

Accès ouvert 2023 supplementary-materials OpenAlex

Supplementary Figure Legend from BAY 1000394, a Novel Cyclin-Dependent Kinase Inhibitor, with Potent Antitumor Activity in Mono- and in Combination Treatment upon Oral Application

Gerhard Siemeister, Ulrich Lücking, Antje M. Wengner, Philip Lienau et autres

0 citations

Accès ouvert 2023 supplementary-materials OpenAlex

Supplementary Table 4 from BAY 1000394, a Novel Cyclin-Dependent Kinase Inhibitor, with Potent Antitumor Activity in Mono- and in Combination Treatment upon Oral Application

Gerhard Siemeister, Ulrich Lücking, Antje M. Wengner, Philip Lienau et autres

0 citations

Accès ouvert 2023 supplementary-materials OpenAlex

Supplementary Table 2 from BAY 1000394, a Novel Cyclin-Dependent Kinase Inhibitor, with Potent Antitumor Activity in Mono- and in Combination Treatment upon Oral Application

Gerhard Siemeister, Ulrich Lücking, Antje M. Wengner, Philip Lienau et autres

0 citations

Accès ouvert 2023 supplementary-materials OpenAlex

Supplementary Table 3 from BAY 1000394, a Novel Cyclin-Dependent Kinase Inhibitor, with Potent Antitumor Activity in Mono- and in Combination Treatment upon Oral Application

Gerhard Siemeister, Ulrich Lücking, Antje M. Wengner, Philip Lienau et autres

0 citations

Accès ouvert 2023 supplementary-materials OpenAlex

Supplementary Figure Legend from BAY 1000394, a Novel Cyclin-Dependent Kinase Inhibitor, with Potent Antitumor Activity in Mono- and in Combination Treatment upon Oral Application

Gerhard Siemeister, Ulrich Lücking, Antje M. Wengner, Philip Lienau et autres

0 citations

Accès ouvert 2023 supplementary-materials OpenAlex

Supplementary Table 5 from BAY 1000394, a Novel Cyclin-Dependent Kinase Inhibitor, with Potent Antitumor Activity in Mono- and in Combination Treatment upon Oral Application

Gerhard Siemeister, Ulrich Lücking, Antje M. Wengner, Philip Lienau et autres

0 citations

Profil ORCID Notice OpenAlex

BNTIC News n’est pas le producteur de ces données. Les publications sont interrogées à la demande dans Crossref, OpenAIRE, DOAJ, Europe PMC, HAL, DataCite, AfricArXiv, ROR et la Banque mondiale, sans clé d’accès. OpenAlex reste optionnel. Aucun service payant n’est nécessaire et aucune donnée externe n’est enregistrée en base. Consulter les sources et leurs limites.